ArticleNature communications2025
A self-directed Trojanbot-enzymatic nanobot in neutrobot for active target therapy of glioblastoma.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Single-cell transcriptome-guided biomimetic magnetothermal hydrogel microspheres for multimodal eradication of residual glioblastoma.Bioactive materials · 2026Article
- Ferritin-Based Nanomotors for Deep Glioblastoma Penetration and Enhanced Drug Delivery.Macromolecular bioscience · 2026Article
- CD5Science advances · 2026Article
- Targeting mNature communications · 2026Article
- Biomimetic Nanoplatform for Targeted Glioblastoma Therapy via Concurrently Triggering GPX4/DHODH Mediated Ferroptosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Reinforcing Calcium Overload via Inflammation-Mediated Targeting to Amplify Pyroptosis and Antitumor Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Magnetic medical microrobots with memory-capable genetic circuits.Science advances · 2026Article
- Janus nanomotors for topical treatment of radiation-induced dermatitis.Nature communications · 2026Article
- Two-dimensional NIR-II AIE nanotheranostic probes with ultralarge Stokes shifts for surgical navigation and ablation of glioma.Science advances · 2026Article
- Engineered Small Extracellular Vesicles Targeting Tumor-Associated Endothelial Cells to Effectively Remodel the Glioma Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Overcoming tumor microenvironment barriers: transformable and bioinspired nanomedicine strategies for deep tumor penetration.Journal of nanobiotechnology · 2026Review
- Cell-drug conjugates: a novel drug delivery system for cancer therapy.Theranostics · 2026Review
- Nanorobots crossing the blood-brain barrier for targeted chemotherapy: the next frontier.Annals of medicine and surgery (2012) · 2026Article
- MRI-Guided Magnetic Micro/Nanorobots for Precision Neurotherapeutics: From Intelligent Navigation and BBB Penetration to Clinical Translation.International journal of nanomedicine · 2026Review
- Biohybrid nanorobots induce lactate isomer conversion to reverse the immune environment and promote tumor therapy.Science advances · 2025Article
- Emerging Insights into the Role of Macrophages in Multiple Sclerosis: Pathogenesis and Potential Therapeutic Strategies.Journal of inflammation research · 2025Review
- Advances in tumor-associated macrophage-mediated chemotherapeutic resistance in glioma.Frontiers in cell and developmental biology · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Chemotherapy is an important treatment for glioblastoma (GBM) and a key component of comprehensive GBM therapy. However, the blood-brain barrier (BBB) and complex tumor microenvironment (TME) restrict the diffusion of drugs, which greatly reduces the chemotherapeutic effect on GBM. Single strategies, such as cell-based nanobots to cross the BBB or enzymatic nanobots propelled by enriched substrates in the TME for deep tumor penetration, remain inadequate to address multiple barriers and achieve precise targeting. Here, we develop a Trojan horse-inspired enzymatic nanobot-in-neutrobot system (Trojanbot) to greatly enhance targeted GBM therapy. Trojanbots traverse the BBB by leveraging positive chemotaxis in response to tumor-derived chemokine gradients, after which the released catalase-driven nanobots (CatNbot) undergo directional movement along the H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.